| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | Head of R&D, CMO | Stock Options (Right to buy) | 144,700 | $2,956,221 | $20.43 | 04 Feb 2026 | Direct |
| Syndax Pharmaceuticals Inc | Head of R&D, CMO | Common Stock | 95,165 | $1,999,416 | $21.01 | 04 Feb 2026 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| SNDX | Syndax Pharmaceuticals Inc | 04 Feb 2026 | 3 | +$2,956,221 | 4 | Head of R&D, CMO | 06 Feb 2026, 16:50 |
| SNDX | Syndax Pharmaceuticals Inc | 16 May 2025 | 1 | +$105,826 | 4 | Head of R&D, CMO | 19 May 2025, 16:03 |
| SNDX | Syndax Pharmaceuticals Inc | 12 May 2025 | 0 | $0 | 3 | Head of R&D, CMO | 16 May 2025, 16:16 |